{"id":35077,"date":"2025-06-11T23:26:54","date_gmt":"2025-06-11T15:26:54","guid":{"rendered":"https:\/\/flcube.com\/?p=35077"},"modified":"2025-06-11T23:26:55","modified_gmt":"2025-06-11T15:26:55","slug":"huadong-medicine-receives-nmpa-approval-for-phase-iii-trial-of-roflumilast-foam","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=35077","title":{"rendered":"Huadong Medicine Receives NMPA Approval for Phase III Trial of Roflumilast Foam"},"content":{"rendered":"\n

China-based Huadong Medicine Co., Ltd (SHE: 000963<\/a>) announced that Its wholly-owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd has received approval from the National Medical Products Administration (NMPA) to initiate a Phase III clinical study for its 0.3% roflumilast foam (trade name: Zorvye). The study will evaluate the drug as a topical treatment for seborrheic dermatitis in patients aged 9 years and older.<\/p>\n\n\n\n

Drug Mechanism<\/strong>
Roflumilast, a phosphodiesterase-4 (PDE4) inhibitor, works by reducing pro-inflammatory mediators and increasing anti-inflammatory mediators, thereby alleviating inflammation. This mechanism of action makes it effective in treating inflammatory skin conditions.<\/p>\n\n\n\n

Licensing and Previous Approvals<\/strong>
Licensed from US-based Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT<\/a>), roflumilast foam was previously approved in the US and Canada for seborrheic dermatitis. It also received FDA approval in May 2025 for the treatment of scalp and body psoriasis in patients aged 12 and older.<\/p>\n\n\n\n

Clinical Trial Results<\/strong>
Clinical studies have demonstrated the strong safety and tolerability of roflumilast foam in patients with seborrheic dermatitis. Notably, 80% of patients achieved complete or near-complete clearance by Week 8 of the trials.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that Its wholly-owned subsidiary Hangzhou Zhongmei Huadong…<\/p>\n","protected":false},"author":1,"featured_media":35078,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[125,62,114,887,4142],"class_list":["post-35077","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-arcutis-biotherapeutics","tag-clinical-trial-approval-initiation","tag-huadong-medicine","tag-she-000963","tag-zhongmei-huadong-pharmaceutical"],"yoast_head":"\nHuadong Medicine Receives NMPA Approval for Phase III Trial of Roflumilast Foam - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received approval from the National Medical Products Administration (NMPA) to initiate a Phase III clinical study for its 0.3% roflumilast foam (trade name: Zorvye). The study will evaluate the drug as a topical treatment for seborrheic dermatitis in patients aged 9 years and older.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=35077\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Huadong Medicine Receives NMPA Approval for Phase III Trial of Roflumilast Foam\" \/>\n<meta property=\"og:description\" content=\"China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received approval from the National Medical Products Administration (NMPA) to initiate a Phase III clinical study for its 0.3% roflumilast foam (trade name: Zorvye). The study will evaluate the drug as a topical treatment for seborrheic dermatitis in patients aged 9 years and older.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=35077\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-11T15:26:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-11T15:26:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1106-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35077#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35077\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Huadong Medicine Receives NMPA Approval for Phase III Trial of Roflumilast Foam\",\"datePublished\":\"2025-06-11T15:26:54+00:00\",\"dateModified\":\"2025-06-11T15:26:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35077\"},\"wordCount\":185,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35077#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1106-1.webp\",\"keywords\":[\"Arcutis Biotherapeutics\",\"Clinical trial approval \\\/ initiation\",\"Huadong Medicine\",\"SHE: 000963\",\"Zhongmei Huadong Pharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35077#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35077\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=35077\",\"name\":\"Huadong Medicine Receives NMPA Approval for Phase III Trial of Roflumilast Foam - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35077#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35077#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1106-1.webp\",\"datePublished\":\"2025-06-11T15:26:54+00:00\",\"dateModified\":\"2025-06-11T15:26:55+00:00\",\"description\":\"China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received approval from the National Medical Products Administration (NMPA) to initiate a Phase III clinical study for its 0.3% roflumilast foam (trade name: Zorvye). The study will evaluate the drug as a topical treatment for seborrheic dermatitis in patients aged 9 years and older.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35077#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35077\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35077#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1106-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1106-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Huadong Medicine Receives NMPA Approval for Phase III Trial of Roflumilast Foam\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35077#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Huadong Medicine Receives NMPA Approval for Phase III Trial of Roflumilast Foam\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Huadong Medicine Receives NMPA Approval for Phase III Trial of Roflumilast Foam - Insight, China's Pharmaceutical Industry","description":"China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received approval from the National Medical Products Administration (NMPA) to initiate a Phase III clinical study for its 0.3% roflumilast foam (trade name: Zorvye). The study will evaluate the drug as a topical treatment for seborrheic dermatitis in patients aged 9 years and older.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=35077","og_locale":"en_US","og_type":"article","og_title":"Huadong Medicine Receives NMPA Approval for Phase III Trial of Roflumilast Foam","og_description":"China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received approval from the National Medical Products Administration (NMPA) to initiate a Phase III clinical study for its 0.3% roflumilast foam (trade name: Zorvye). The study will evaluate the drug as a topical treatment for seborrheic dermatitis in patients aged 9 years and older.","og_url":"https:\/\/flcube.com\/?p=35077","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-11T15:26:54+00:00","article_modified_time":"2025-06-11T15:26:55+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1106-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=35077#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=35077"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Huadong Medicine Receives NMPA Approval for Phase III Trial of Roflumilast Foam","datePublished":"2025-06-11T15:26:54+00:00","dateModified":"2025-06-11T15:26:55+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=35077"},"wordCount":185,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=35077#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1106-1.webp","keywords":["Arcutis Biotherapeutics","Clinical trial approval \/ initiation","Huadong Medicine","SHE: 000963","Zhongmei Huadong Pharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=35077#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=35077","url":"https:\/\/flcube.com\/?p=35077","name":"Huadong Medicine Receives NMPA Approval for Phase III Trial of Roflumilast Foam - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=35077#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=35077#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1106-1.webp","datePublished":"2025-06-11T15:26:54+00:00","dateModified":"2025-06-11T15:26:55+00:00","description":"China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received approval from the National Medical Products Administration (NMPA) to initiate a Phase III clinical study for its 0.3% roflumilast foam (trade name: Zorvye). The study will evaluate the drug as a topical treatment for seborrheic dermatitis in patients aged 9 years and older.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=35077#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=35077"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=35077#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1106-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1106-1.webp","width":1080,"height":608,"caption":"Huadong Medicine Receives NMPA Approval for Phase III Trial of Roflumilast Foam"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=35077#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Huadong Medicine Receives NMPA Approval for Phase III Trial of Roflumilast Foam"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1106-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35077","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=35077"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35077\/revisions"}],"predecessor-version":[{"id":35079,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35077\/revisions\/35079"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/35078"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=35077"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=35077"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=35077"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}